FDA faults IQVIA for errors in opioid sales data, calls for quality review
The FDA is calling upon IQVIA to review its data quality and methodologies after finding errors regarding sales volume data on certain controlled substance, including opioids. Citing “serious concerns about systemic issues with IQVIA’s data and quality control procedures,” the agency has requested IQVIA run an independent audit.
In a statement, IQVIA — the world’s largest clinical outsourcing firm and a widely used data vendor — said it’s been addressing the issue, which it had already identified prior to the notification. It also says it’s working with the FDA to resolve concerns — something that the FDA acknowledged in its own release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.